ArticleRadiation oncology (London, England)2021

Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.

Xiaoyang Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.